Form 4 for HOWL Werewolf Therapeutics, Inc.
Accepted 2026-01-02 00:00:00 ET · period of report 2025-12-30 · accession 0001134657-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-01-02 | 2025-12-30+ | HOWL | EVNIN LUKE | Dir | S - Sale | $0.6179 | -78.4K | 2.47M | -3% | -$48.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-30 | S | D | 34,847 | $0.61 | 2,515,827 | I See Footnotes | — | — | (F2) The shares were sold as follows: 3,728 by MPM Asset Management LLC ("AM LLC"), 23,551 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,571 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 811 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 5,186 by MPM Oncology Innovations Fund, L.P. ("MPM OIF"). (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6085 to $0.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F5) The shares are held as follows: 269,490 by AM LLC, 1,701,633 by BV 2014, 113,495 by BV 2014(B), 58,568 by AM BV2014 and 372,641 by MPM OIF. (F4) MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| 2 | Common | Common Stock | 2025-12-31 | S | D | 24,962 | $0.62 | 2,490,865 | I See Footnotes | — | — | (F6) The shares were sold as follows: 2,670 by AM LLC, 16,870 by BV 2014, 1,125 by BV 2014(B), 582 by AM BV2014 and 3,715 by MPM OIF. (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6038 to $0.6359 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F4) MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. (F8) The shares are held as follows: 266,820 by AM LLC, 1,684,763 by BV 2014, 112,370 by BV 2014(B), 57,986 by AM BV2014 and 368,926 by MPM OIF. |
| 3 | Common | Common Stock | 2026-01-02 | S | D | 18,568 | $0.63 | 2,472,297 | I See Footnotes | — | — | (F9) The shares were sold as follows: 1,986 by AM LLC, 12,549 by BV 2014, 837 by BV 2014(B), 432 by AM BV2014 and 2,764 by MPM OIF. (F10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.6499 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F11) The shares are held as follows: 264,834 by AM LLC, 1,672,214 by BV 2014, 111,533 by BV 2014(B), 57,554 by AM BV2014 and 366,162 by MPM OIF. (F4) MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |